PBLA - Panbela Therapeutics dips 24% on pricing $6M public offering

• Panbela Therapeutics ( NASDAQ: PBLA ) prices a public offering of (i) 20.1M shares of stock, warrants to purchase up to 30.15M shares at a purchase price of $0.30.
• Warrants will have an exercise price of $0.30 per share, are exercisable upon issuance, and will expire five years following the date of issuance.
• Offering is expected to close on or about October 4, 2022.
• Gross proceeds of $6M.
• Net proceeds to be deployed for the continued clinical development of its product candidates ivospemin (SBP-101) and eflornithine (CPP-1X), working capital, business development and other general corporate purposes, which may include repayment of debt.
• Stock drops 24% pre-market

For further details see: